Piper Sandler Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

Key Points

• Piper Sandler cut its price target on TransMedics from $160 to $120 but kept an "overweight" rating, with the $120 target implying roughly 63.8% upside from the recent close.
• TransMedics missed Q1 EPS ($0.30 vs. $0.62 expected) and slightly missed revenue, driving the stock to $73.26 on heavy volume, even as revenue rose 21.2% YoY and profitability remained strong (net margin ~31%, ROE ~30%).
• Street sentiment is mixed—six Buys and six Holds with a consensus price target of $144.33—and recent analyst shifts plus sizable insider selling (including director and CFO sales; ~16,205 shares in 90 days) have added near-term selling pressure.

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price objective cut by analysts at Piper Sandler from $160.00 to $120.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Piper Sandler's price target points to a potential upside of 63.80% from the stock's previous close.

TMDX has been the topic of several other reports. Oppenheimer downgraded shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a "neutral" rating in a report on Wednesday, February 25th. Stifel Nicolaus raised their price target on TransMedics Group from $115.00 to $130.00 and gave the stock a "hold" rating in a report on Monday, March 9th. TD Cowen reaffirmed a "buy" rating on shares of TransMedics Group in a report on Monday, March 16th. Finally, Wall Street Zen lowered TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $144.33.

TransMedics Group Stock Performance

TMDX traded down $21.67 during trading hours on Wednesday, hitting $73.26. The stock had a trading volume of 3,976,214 shares, compared to its average volume of 934,086. TransMedics Group has a 1 year low of $71.67 and a 1 year high of $156.00. The company's fifty day simple moving average is $116.57 and its 200 day simple moving average is $125.96. The stock has a market cap of $2.53 billion, a PE ratio of 14.90 and a beta of 2.07. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to analysts' expectations of $174.48 million. TransMedics Group had a net margin of 31.43% and a return on equity of 30.17%. TransMedics Group's revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period last year, the company earned $0.70 earnings per share. Equities analysts anticipate that TransMedics Group will post 2.48 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, Director Stephanie Lovell sold 1,193 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the sale, the director owned 2,866 shares of the company's stock, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the sale, the chief financial officer directly owned 14,689 shares of the company's stock, valued at $2,162,367.69. This represents a 33.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 16,205 shares of company stock valued at $2,353,002. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently added to or reduced their stakes in the business. D.A. Davidson & CO. boosted its stake in TransMedics Group by 0.5% during the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company's stock valued at $1,865,000 after buying an additional 83 shares during the period. Parallel Advisors LLC boosted its stake in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company's stock valued at $34,000 after buying an additional 83 shares during the period. HighPoint Advisor Group LLC boosted its stake in TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company's stock valued at $359,000 after buying an additional 88 shares during the period. Crossmark Global Holdings Inc. boosted its stake in TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company's stock valued at $277,000 after buying an additional 88 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock valued at $482,000 after buying an additional 100 shares during the period. Institutional investors own 99.67% of the company's stock.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Solid top-line growth and strong profitability metrics: Q1 revenue rose ~21.2% year-over-year and the business reported a healthy net margin (31.4%) and ROE (~30%). These fundamentals support longer-term growth expectations. MarketBeat Q1 report
• Positive Sentiment: Needham kept a Buy rating and set a $142 price target (lowered from $174) — signaling continued analyst conviction and implying significant upside from current levels despite the cut. Benzinga note on Needham
• Neutral Sentiment: FY‑2026 revenue guidance was reiterated/updated to $727M–$757M (range that roughly brackets consensus), leaving investors to parse whether guidance implies conservatism or is in line with expectations. PR Newswire release
• Neutral Sentiment: Earnings call transcript and supplemental materials are available for details on product adoption, backlog and margin drivers—useful for modeling but not immediate market movers absent new guidance. Seeking Alpha transcript
• Negative Sentiment: Q1 EPS missed expectations: reported $0.30 vs. consensus ~$0.62 and sharply below last year’s $0.70, flagging pressure on near-term profitability per-share and driving immediate downside. Revenue also slightly missed consensus. Zacks coverage of the miss
• Negative Sentiment: Analyst downgrade from Oppenheimer (Outperform → Market Perform) adds selling pressure and reduces near-term enthusiasm from institutional buyers. Finviz note on downgrade

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.